anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Depression is a serious mental health problem that affects millions of people globally. Anhedonia, a core symptom of depression, is the loss of pleasure or interest in enjoyable activities. The presence of anhedonia is a risk factor of poor outcome of depression. Although some patients reach remission after treatment, anhedonia still persists as a residual symptom. It is generally believed that the frontal-striatal pathway plays an important role in the reward system of brain in patients with depression. The mechanism of anhedonia is closely related to the function of the brain's reward system dopamine. There have been some research showed benefits of playing video games on brain. Video games can modulate negative emotions and increase positive feelings. Previous studies have confirmed that playing games will activate the release of dopamine in striatum. "Dancing Line" is a commercial music game. Participants need to change the direction of target according to the music by tapping the screen and manage to finish the routes and get the gems along the route as much as possible. Sometimes the view of participants would change during the game. The game is simple for participants to pick up and there is no need for prior gaming experience. The main purpose of the study is to explore the effect of game as an adjuvant treatment on anhedonia, depressive symptoms, cognitive function and associated functional change of brain in patients with depression.
The invention provides a recombinant methylotrophic bacterium and an oral vaccine, belonging to the technical field of biotechnology genetic engineering, wherein a pSCM15 plasmid and a pSCM16 plasmid are electrically transformed into the methylotrophic bacterium to obtain the recombinant methylotrophic bacterium; the nucleotide sequence of the pSCM15 plasmid is shown as SEQ ID No. 1; the nucleotide sequence of the pSCM16 plasmid is shown as SEQ ID No. 2. After the turbot is immunized by the oral vaccine prepared from the recombinant methylotrophic bacterium, the serum antibody titer is detected by ELISA, and the immune effect of feeding the oral vaccine is obvious. Compared with the immune effect through a soaking challenge experiment, the immune protection rate of the turbot is 80 percent. Therefore, the oral vaccine of the recombinant methylotrophic bacteria has excellent immune protection capability, can assist in controlling the harm of some important pathogenic microorganisms to the health of cultured animals and fishery culture, and realizes green culture.
There have been conflicting reports about the concomitant use of neomycin and lactulose solution. Theoretically, the elimination of certain colonic bacteria by neomycin and possibly other anti-infective agents may interfere with the desired degradation of lactulose and thus prevent the acidification of colonic contents. Thus the status of the lactulose-treated patient should be closely monitored in the event of concomitant oral anti-infective therapy.

Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose.

Other laxatives should not be used, especially during the initial phase of therapy for portal-systemic encephalopathy, because the loose stools resulting from their use may falsely suggest that adequate lactulose dosage has been achieved.
PURPOSE:The titled composition capable of raising endermic permeability of ion dissociating drug even at low voltage and at low electric current, containing a specific compound such as 1-dodecylazacycloheptan-2-one, etc. CONSTITUTION:The titled compound containing a compound shown by the formula (R is H or lower alkyl; m is 5-7; n is 0-17) as an essential component. When the compound shown by the formula is blended with anion dissociating drug (having <=1,000, especially <=500mol.wt.), the blend itself can be used as a biological electrode. Further the composition is blended with urea (e.g., a polar, hydrophilic solvent such as a cyclic urea (e.g., N,N-dimethylethyleneurea), a lactam compound (e.g., N-methyl-2-pyridone), etc., and, if necessary, water. Preferably the composition is supported on a drug holding material, which is applied to a conductive material such as a metallic plate, etc., or put in a metallic container and used as the biological electrode.
The invention discloses a method for synthesizing a gel preparation for treating hyperosteogeny. The main steps are 1) preparation of PLGA-PEG-PLGA gel solution; 2) preparing the NSAIDs-PTT therapeutic gel by a mixing method. The gold nanoparticles have excellent photo-thermal property and photo-thermal conversion property, and can effectively convert light energy into heat energy, thereby removing abnormal cells or tissues. Non-steroidal anti-inflammatory drugs (NSAIDS) are a class of non-steroidal hormones capable of eliminating pain, swelling, stiffness in limbs and inflammation. Non-steroidal anti-inflammatory drugs are commonly used in painful conditions including arthritis, bursitis, tendonitis, gout, menstrual cramps, sprains, strains and other injuries. PLGA-PEG-PLGA is nontoxic and has good biocompatibility, is in a liquid state at normal temperature, is changed into gel at about 35 ℃, is well used for in vivo injection, prolongs the retention of the medicine in vivo and further improves the treatment effect.
OBJECTIVES: To evaluate the safety and efficacy of switching from intravenous (IV) to oral antimicrobial therapy in patients with Enterobacterales bacteraemia, after completion of 3-5 days of microbiologically active IV therapy.
METHODS: A multicentre, open-label, randomized trial of adults with monomicrobial Enterobacterales bacteraemia caused by a strain susceptible to ≥1 oral beta-lactam, quinolone, or trimethoprim/sulfamethoxazole. Inclusion criteria included completion of 3-5 days of microbiologically active IV therapy, being afebrile and haemodynamically stable for ≥48 hours, and absence of an uncontrolled source of infection. Pregnancy, endocarditis, and neurological infections were exclusion criteria. Randomization, stratified by urinary source of bacteraemia, was to continue IV (IV Group) or to switch to oral therapy (Oral Group). Agents and duration of therapy were determined by the treating physicians. The primary endpoint was treatment failure, defined as death, need for additional antimicrobial therapy, microbiological relapse, or infection-related re-admission within 90 days. Non-inferiority threshold was set at 10% in the 95% CI for the difference in the proportion with treatment failure between the Oral and IV Groups in the modified intention-to-treat population. The protocol was registered at ClinicalTrials.gov (NCT04146922).
RESULTS: In the modified intention-to-treat population, treatment failure occurred in 21 of 82 (25.6%) in the IV Group, and 18 of 83 (21.7%) in the Oral Group (risk difference -3.7%, 95% CI -16.6% to 9.2%). The proportions of subjects with any adverse events (AE), serious AE, or AE leading to treatment discontinuation were comparable.
DISCUSSION: In patients with Enterobacterales bacteraemia, oral switch, after initial IV antimicrobial therapy, clinical stability, and source control, is non-inferior to continuing IV therapy.
PURPOSE:Mouthwash which forms a film of a composition, is conveniently portable and can carry out mouth washing anywhere simply, obtained by blend ing pullulan with a surface active agent and a polyhydric alcohol in a specific ratio. CONSTITUTION:100pts.wt. pullulan is blended with 0.1-30pts.wt. surface active agnet (e.g., sodium lauryl sulfate, sodium myristyl sulfate, sodium lauroyl sarcosinate, etc.,) and 5-30pts.wt. polyhydric alcohol (e.g., glycerin, ethylene glycol, propylene glycol, sorbitol, sucrose, etc.,) and a film of a composition is formed in an inner wall of a container for gargling to give mouthwash. The composition may be optionally blended with a sweetener such as saccharin, antiseptic, active ingredient such as sodium chloride, etc., perfume such as anethole, etc., in ranges not to damage film forming ability, film adhesivity and feeling in use.
12.1 How Supplied

Trubrexa TMTransdermal Patch comes in a sealed pouch bag. Each patch is 2 in x 2 in (5.08 cm x 5.08 cm) and consists of an adhesive side containing the active/inactive ingredients and an outer surface backing layer. The adhesive side is covered with a removable, clear, unprinted, plastic film. The outer surface of the backing layer is imprinted with the Trubrexa TMTransdermal Patch logo. 

Trubrexa TMTransdermal Patch is available as a unit box containing 32 patches (8 pouch bags). NDC 83295-4000-1 

12.2 Storage

Store unit box between 68 o-77 oF (20 o-25 oC). Excursions between 15 o-30 oC (59 o-86 oF) are allowed. Keep Trubrexa TMTransdermal Patch in the sealed pouch bags until immediately before use. 

12.3 Handling and Disposal

Unintended exposure to capsaicin can cause severe irritation of eyes, skin, respiratory tract, and mucous membranes. Avoid contact with your eyes, nose, or mouth. Keep used and unused patches out of the reach of children and pets. Pouch bags are not child resistant. Wash hands with soap and water after handling the patch. If irritation or a burning sensation occurs during application, remove the patch and do not reapply until the irritation subsides. After use, fold patches so that the adhesive side sticks to itself, then safely discard used patches where children and pets cannot get to them.
Individuals, and where possible multiple family members, from families with inherited Parkinson's disease will be enrolled. We will also be enrolling people with sporadic Parkinson's disease. Known disease genes will be sequenced to look for mutations. In the event that no mutations are detected and there are samples from multiple family members, linkage analysis will be undertaken in an effort to identify a region or regions of the genome harboring defective genes that cause inherited Parkinson's disease. Candidate genes that reside in regions linked to the disease will be sequenced in effort to find mutations responsible for the disease.

Genetic linkage studies will include all available, informative family members, while gene sequence analysis will be performed on affected individuals and spousal controls. In the event that we identify a mutation of clear pathogenicity in one of the known Parkinson's genes, we will contact all participating family members to notify them of the discovery of the gene that causes PD in their family and offer them individual counseling and testing in a CLIA approved lab. To assess any impact caused by the offer and subsequent pursuit of genetic testing we will be administering a questionnaire assessing psychological well-being prior to and following testing.
This study will focus on patients who are opioid-tolerant pre-operatively, a patient population which typically has both higher pain scores and more complications related to analgesics than opioid naïve patients. Currently, there is no standardized system for determining an adequate pain control regimen for a patient post-operatively. At this institution, pain medications are dosed per physician preference. The most widely-discussed method for calculating tolerance to opioids relies on converting a patient's daily opioid consumption to a morphine equivalent dose and basing a pain regimen upon that number. This method does not account for variability of response to different medications or dosing forms however. It would be advantageous to have a method of dosing opioid pain medications in this population that is both safe and effective.
The invention relates to a healthy beverage which has the functions of strengthening the body, tonifying kidney and yang, nourishing yin and the like as prepared matter can adjust hormones generated by in vivo pituitary gland, thyroid gland and genital gland and improve sexual hormones. A preparation method comprises the following steps: with magnetized stony edema as a base material, dosing. The beverage is prepared from eleven components: botanic MACA of abnormal fruits, vegetable and fruit type okra, cordyceps sinensis, cistanche, sealwort, glossy privet fruits, Chinese wolfberries, fresh ginger, peanuts (shells), hawthorn and fructose. The beverage is reasonable in formula and precise and appropriate in combination, meets the complementary theory of herbaceous plants and dietary therapy and can exert the unique effect. By adopting a high-tech yaguo (butane and the like) low-temperature extraction method, nutritional essence is concentrated and extracted. The beverage aims to treat disease of prostate caused by prevailing low sexual capacity of males and sexual apathy of females so as to powerfully enhance secretion of hormones in the body, so that the sexual energy is improved and the national constitutions are strengthened.
A novel purified phosphoprotein designated mitosin is provided by this invention. Also provided is the amino acid sequence and nucleic acid molecule corresponding to mitosin protein. Diagnostic and therapeutic methods using the protein and nucleic acid molecule also are provided. A nucleic acid molecule encoding mitosin also is provided by this invention, as well as active fragments thereof. The nucleic acid molecules are useful to recombinantly produce mitosin and for use as probes. The compositions and methods of this invention are based on the instant discovery that the intracellular presence of mitosin is necessary for a eukaryotic cell to enter into the M phase of mitosis, and that the degradation of mitosin is necessary for the cell to advance to the next stage. Thus, an anti-mitosin antibody, a mutant or a non-functional analog of mitosin would inhibit the mitotic cell cycle by preventing cells from entering the M phase, and overexpression of mitosin, or a functional equivalent thereof, would inhibit the cycle by preventing cells from leaving the M phase. Such overexpression could be achieved either by addition of the protein or through gene therapy, i.e. delivery of a gene encoding the protein or a functional equivalent thereof.
In this arm, 50 patients with extensive-stage small cell lung cancer or relapsed within more than 6 months after SCLC radical treatment will receive 4 circles of toripalimab and JS004 combined with platinum-based doublet chemotherapy. Then patients received maintenance treatment with toripalimab and JS004 until the disease progressed.
Diazepam rectal gel adverse event data were collected from double-blind, placebo-controlled studies and open-label studies. The majority of adverse events were mild to moderate in severity and transient in nature.

Two patients who received diazepam rectal gel died seven to 15 weeks following treatment; neither of these deaths was deemed related to diazepam rectal gel.

The most frequent adverse event reported to be related to diazepam rectal gel in the two double-blind, placebo-controlled studies was somnolence (23%). Less frequent adverse events were dizziness, headache, pain, abdominal pain, nervousness, vasodilatation, diarrhea, ataxia, euphoria, incoordination, asthma, rhinitis, and rash, which occurred in approximately 2-5% of patients.

Approximately 1.4% of the 573 patients who received diazepam rectal gel in clinical trials of epilepsy discontinued treatment because of an adverse event. The adverse event most frequently associated with discontinuation (occurring in three patients) was somnolence. Other adverse events most commonly associated with discontinuation and occurring in two patients were hypoventilation and rash. Adverse events occurring in one patient were asthenia, hyperkinesia, incoordination, vasodilatation and urticaria. These events were judged to be related to diazepam rectal gel.

In the two domestic double-blind, placebo-controlled, parallel-group studies, the proportion of patients who discontinued treatment because of adverse events was 2% for the group treated with diazepam rectal gel, versus 2% for the placebo group. In the diazepam rectal gel group, the adverse events considered the primary reason for discontinuation were different in the two patients who discontinued treatment; one discontinued due to rash and one discontinued due to lethargy. The primary reason for discontinuation in the patients treated with placebo was lack of effect.
Large-volume therapeutic phlebotomy is the mainstay of hemochromatosis treatment and offers an opportunity to investigate the hemodynamic changes during acute hypovolemia. An otherwise healthy 64-year-old male with hemochromatosis participated. On nine separate visits, 1000 mL therapeutic phlebotomy was performed. On one occasion, pre- and post-phlebotomy orthostatic challenge with 27° reverse Trendelenburg position was administered. Mean arterial pressure, heart rate, and stroke volume were measured continuously during the procedures. The patient's tolerance to the interventions was continuously evaluated. The procedures were well tolerated by the patient. Mean arterial pressure was maintained during hemorrhage and following phlebotomy in both supine and reverse Trendelenburg positions, primarily through an increase in heart rate and systemic vascular resistance. The present study found that 1000 mL therapeutic phlebotomy in a patient with hemochromatosis may be acceptably and safely used to model hemorrhage. The approach demonstrates high clinical applicability and ethically robustness in comparison with volunteer studies.
The plyometric training group participated in a 6-week training program performing a variety of plyometric exercises designed for the lower extremity , while the control group did not participate in any plyometric exercises. All subjects were instructed not to start any lower extremity strengthening programs during the 6-week period and to only perform activities of normal daily living.
Enalapril maleate oral solution is the maleate salt of enalapril, the ethyl ester prodrug of a long-acting angiotensin-converting enzyme inhibitor, enalaprilat. Enalapril maleate is chemically described as (S)-1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline, (Z)-2-butenedioate salt (1:1). Its empirical formula is C20H28N2O5•C4H4O4, and its structural formula is:

Enalapril maleate is a white to off-white, crystalline powder with a molecular weight of 492.52. It is sparingly soluble in water, soluble in ethanol, and freely soluble in methanol. 

Enalapril maleate oral solution is a ready-to-use oral solution. Each 1 mL contains 1 mg of enalapril maleate, USP equivalent to 0.764 mg of enalapril. Inactive ingredients include citric acid, mixed berry flavor, purified water, sodium benzoate, sodium citrate, and sucralose. It may also contain hydrochloric acid or sodium hydroxide for pH adjustment. Enalapril maleate oral solution is clear and colorless.
Systems for assisting a user in performance of a meditation activity or another type of activity are described. The systems receive user input and sensor data indicating physiological values associated with the user. These values are used to determine a recommended type of activity and a length of time for the activity. While the user performs the activity, sensors are used to measure physiological values, and an output that is provided to the user is selected based on the measured physiological values. The output may be selected to assist the user in reaching target physiological values, such as a slower respiration rate. After completion of the activity, additional physiological values are used to determine the effectiveness of the activity and the output that was provided. The effectiveness of the activity and the output may be used to determine future recommendations and future output.
The 50 mL Pharmacy Bulk Package is for use in the Pharmacy Admixtures Service only. 

A single entry through the bottle closure should be made with a sterile dispensing set or transfer device. Transfer individual doses to appropriate intravenous infusion solutions. Use of a syringe with needle is not recommended. Multiple entries will increase the potential of microbial and particulate contamination. 

The above process should be carried out under a laminar flow hood using aseptic technique. Care should be exercised to protect personnel from aerosolized drug (see DOSAGE AND ADMINISTRATION, REFERENCES). Discard any unused portion within 4 hours after initial closure entry.
This is a prospective observational study where all abnormal antenatal ultrasounds are discussed in a weekly prenatal meeting and plans are drawn for management of these abnormal fetal findings. Lethal malformations are defined as conditions which will end in death regardless of supportive care. Cases are discussed extensively and parents are involved in management decisions. When a decision of non- intervention is reached for a lethal malformation consent of the family is obtained and a plan of non monitoring for the mother is documented together with no resuscitation for the newborn. Families who do not consent to such plan are offered full support for the pregnant mother and her newborn. A record of all cases is kept available together with the management plan so that the appropriate action is taken when the the pregnant lady presents for admission. All babies with lethal malformations are recorded whether stillborn or live born and their diagnosis is confirmed. Survival time is recorded for each case.
Oral Solution

Stavudine for oral solution is a dye-free, fruit-flavored powder that provides 1 mg of stavudine per mL of solution upon constitution with water. Directions for solution preparation are included on the product label and in the Dosage and Administration (2) section of this insert. Stavudine for oral solution (NDC No. 53104-0111-5) is available in child-resistant containers that provide 200 mL of solution after constitution with water.

Storage

Stavudine for oral solution should be protected from excessive moisture and stored in tightly closed containers at 20°C-25°C (68°F-77°F) [See USP Controlled Room Temperature]. After constitution, store tightly closed containers of Stavudine for Oral Solution in a refrigerator, 2°C to 8°C (36°F to 46°F). Discard any unused portion after 30 days.
This non-blinded, randomized controlled pilot study is to be conducted at the Men's Health Clinic in Winnipeg, Manitoba. All eligible patients undergoing circumcision will be invited to participate in the study. They will be randomly assigned in a 1:1 ratio using a computer-generated random list. Patients will be randomized to 2-Octyl cyanoacrylate (2-OCA) with four interrupted sutures vs. standard suturing alone. In the post-operative recovery area, patients will be asked to complete a VAS questionnaire. Patients will then be brought in for their routine visit 6 weeks post-op. During the visit, closure of the wound as well as any potential complications will be assessed by a research team member. At that time, a questionnaire will be administered to study participants to assess variables such as post-procedure pain as well as their satisfaction with the recovery process and cosmesis post-circumcision. Cosmesis and complications will also be assessed 12 weeks post-op.
PURPOSE:To improve the dissolution of orally administered carbocysteine preparation into digestive juice. CONSTITUTION:The objective pharmaceutical preparation is produced by encapsulating a composition composed of carbocysteine having action to regulate the mucosa of respiratory tract and normalize the mucous membrane in combination with an oily base (e.g. edible oil) and an aqueous base (e.g. a nonionic surfactant having an HLB of 1-20). The (edible oil : surfactant) weight ratio is (50-99):(50-1), especially (70-95):(30-5). Carbocysteine is dispersed or dissolved in a surfactant, an edible oil is uniformly mixed to the dispersion, etc., to obtain the content to be encapsulated and the mixture is filled in a capsule case by conventional process to obtain a hard or soft capsule preparation.